Released in June 2024, the FDA’s draft guidance on Essential Drug Delivery Outputs (EDDO) provides critical recommendations for industry stakeholders involved in the development, production, and marketing of drug delivery devices and combination products. This guidance aims to ensure that medical devices intended for drug delivery perform as expected, guaranteeing patient safety and product efficacy.
Introduction
The FDA’s guidance document addresses the crucial aspects of drug delivery performance information for devices and combination products that include device constituent parts. The guidance outlines the necessary steps to identify, verify, validate, and control the design outputs that are essential for the drug delivery function. The document is comprehensive, covering investigational, marketing, and post-market change applications, thus providing a robust framework for industry stakeholders.
Scope and Definition
Scope
The guidance focuses on the information and data developed and submitted to the FDA regarding EDDOs for devices and combination products intended for drug delivery. Examples of products within the scope of this guidance include syringes, injectors, infusion products, nasal sprays, inhalers, nebulizers, and vaginal systems.
Definition
EDDOs are the design outputs necessary to ensure the delivery of the intended drug dose to the intended delivery site. This includes successful product preparation, the initiation, progression, and completion of dose delivery. EDDOs are system-level outputs for which device drug-delivery function is dependent on the device design.
Background
The guidance is grounded in the design control requirements, which include establishing and maintaining procedures relating to design inputs and design outputs as per 21 CFR 820.30. The design must be verified and validated throughout the lifecycle of the product as needed. EDDOs are a subset of design outputs that are essential for the proper functioning of the device to deliver the drug. Manufacturers must ensure that EDDOs are identified and approved before release and that they are controlled and maintained throughout the product lifecycle.
Overview of EDDO Processes
In developing EDDOs, three primary processes are emphasized: identification, control, and maintenance.
- Identification: Defines the device drug-delivery function of the product and focuses design and development efforts to ensure appropriate drug delivery.
- Control: Ensures the product meets the device drug-delivery function quality standards.
- Maintenance: Ensures that any changes to the product during clinical development or post-market that could adversely impact the EDDO are evaluated to help preserve the quality of the drug-delivery function.
Identifying Essential Drug Delivery Outputs
Identifying EDDOs involves a filtering process to determine specific design outputs critical for drug delivery. The steps include:
- Design Outputs: Begin by defining the proposed intended use, considering indications for use, population, condition and frequency of use, and design inputs.
- Drug Delivery Design Outputs: Identify those design outputs related to the delivery of the drug, such as the intended dose, delivery to target site, method of delivery, and product preparation.
- System-Level Design Outputs: Identify the drug delivery design outputs that are system-level design outputs, which are necessary for the performance of the final finished product.
- Device-Dependent Design Outputs: Identify the system-level drug delivery design outputs that are independent of the user and dependent on the device design.
Verifying and Validating Essential Drug Delivery Outputs
Verification and validation of EDDOs are critical to ensuring that the device performs as intended. This involves several key activities:
Design Verification
Design verification includes preconditioning and subsequent verification testing to confirm that the device drug-delivery function is maintained in accordance with the instructions for use.
- Preconditioning: Simulates exposing the product to stressors during shipping, storage, and use. Applicants should identify preconditions based on the risk of the product design, intended use, and conditions associated with use.
- Design Verification Testing: Occurs after preconditioning and includes functional testing to verify that an EDDO is maintained throughout the range of conditions and use environments described in proposed labeling.
Design Validation
Design validation ensures that devices conform to defined user needs and intended uses, including testing of production units under actual or simulated use conditions. The appropriate method depends on the application type, stage of development, and EDDO.
- Clinical Studies: May include endpoints relevant to the performance of the device, such as infusion rate, dose range, and injection time.
- Simulated Bench Testing: Evaluates whether users can use the prototype devices over the range of the EDDO specification.
- Anthropometric Data: Uses data to support the proposed injection depth specification or other relevant specifications.
Control Strategies for Essential Drug Delivery Outputs
A robust control strategy is essential to ensure that each lot of the final finished product conforms to the design outputs. This strategy should be risk-based and may involve upstream controls (e.g., in-process controls, control of process parameters) and downstream controls (e.g., lot release testing).
Developing a Control Strategy
When developing a control strategy, it is important to consider the attributes and manufacturing process steps that can influence the EDDO. The control strategy should ensure that the final finished product maintains its EDDOs through appropriate controls at different stages of the manufacturing process.
Information to Provide in Applications
The guidance outlines the EDDO information and performance data to include in investigational, marketing, and post-market change applications to demonstrate the device drug-delivery function.
IND and IDE Applications
For IND and IDE applications, the data provided should reflect the development stage of the product. Information from EDDO verification testing is provided to demonstrate that the device performs and the drug is delivered as intended.
Marketing Applications
Marketing applications for devices and combination products must include a description of the device, acceptance criteria, and performance data verifying and validating the final finished product. This includes a comprehensive description of the device design, functional components, and methods used in manufacture, as well as nonclinical laboratory studies.
Post-Market Changes
When modifying the product design or manufacturing process, applicants should evaluate whether there are any new EDDOs and verify and validate them as appropriate. Post-market change submissions should include a detailed description of the proposed change, a description of the methods used to assess the effects of the change, and the data derived from such studies.
Interaction with FDA
The guidance encourages early engagement with the FDA to discuss EDDOs and control strategies. Applicants are advised to submit proposed EDDOs and control strategies for FDA feedback during product development. This proactive approach can facilitate smoother approval processes and ensure compliance with regulatory requirements.
Appendices
The guidance document includes several appendices with examples and detailed illustrations to aid in the understanding and application of the recommendations:
- Appendix A: Example of EDDO identification for a prefilled syringe.
- Appendix B: EDDO identification for an autoinjector.
- Appendix C: Examples of potential EDDOs based on product type.
- Appendix D: Example of a control strategy for needle extension length in an autoinjector.
Conclusion
The FDA’s draft guidance on Essential Drug Delivery Outputs provides a critical framework for the industry to ensure that drug delivery devices and combination products perform as intended, thereby safeguarding patient safety and product efficacy. By following the detailed recommendations for identifying, verifying, validating, and controlling EDDOs, manufacturers can enhance their compliance with regulatory requirements and improve the quality of their products.
This guidance document, while still in draft form, represents the FDA’s current thinking on essential drug delivery outputs. It underscores the importance of meticulous design control processes and robust control strategies to maintain the quality and safety of drug delivery devices throughout their lifecycle. As the industry continues to evolve, adherence to such comprehensive guidelines will be paramount in ensuring that innovative drug delivery solutions meet the highest standards of safety and effectiveness.
